About
Research in the lab is focused on the functional role and molecular actions of cellular glycosylation and carbohydrate-binding proteins (lectins), in particular galectins, in cancer development, progression and metastasis. The research has a strong element in translational development of galectin-targeted novel therapeutics for treatment of cancer. Our research has led to the launch of a University spin-out biotech company, GALYTX, to accelerate pre-clinical and clinical development of novel galectin inhibitors identified in the laboratory for treatment of cancer and other galectin-associated pathologies. Our research has been supported by various national and international funding agencies including MRC, CRUK, BBSRC, Wellcome Trust, Northwest Cancer Research Fund, Royal Society, American Institute for Cancer Research, World Cancer Research Fund, and Mizutani Foundation for Glycosciences